Biomark Diagnostics Inc. (FRA:20B)
Germany · Delayed Price · Currency is EUR 0.2760
0.00 (0.00%)
At close: Sep 15, 2026
Biomark Diagnostics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 0.03 | 0.06 | 0.15 | 0.16 | 0.15 | 0.04 | |
Revenue Growth | -82.05% | -61.23% | -5.52% | 6.34% | 249.38% | - |
Gross Profit | 0.03 | 0.06 | 0.15 | 0.16 | 0.15 | 0.04 |
Selling, General & Admin | 0.6 | 0.64 | 0.74 | 0.75 | 0.73 | 0.65 |
Research & Development | 0.72 | 0.67 | 0.7 | 0.65 | 0.55 | 0.5 |
Operating Expenses | 1.79 | 1.78 | 2.2 | 1.87 | 1.99 | 1.33 |
Operating Income | -1.76 | -1.72 | -2.05 | -1.71 | -1.84 | -1.28 |
Interest Expense | -0.08 | -0.06 | -0.06 | -0.06 | -0.11 | -0.04 |
Interest & Investment Income | 0.06 | 0.05 | 0 | 0 | 0 | - |
Currency Exchange Gain (Loss) | -0.03 | -0.06 | -0 | 0 | - | -0 |
Other Non Operating Income (Expenses) | 0.39 | 0.32 | 0.18 | 0.34 | 0.11 | -0.13 |
EBT Excluding Unusual Items | -1.43 | -1.48 | -1.93 | -1.43 | -1.84 | -1.45 |
Pretax Income | -1.43 | -1.48 | -1.93 | -1.43 | -1.84 | -1.45 |
Net Income | -1.43 | -1.48 | -1.93 | -1.43 | -1.84 | -1.45 |
Net Income to Common | -1.43 | -1.48 | -1.93 | -1.43 | -1.84 | -1.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 105 | 105 | 91 | 85 | 83 | 78 |
Shares Outstanding (Diluted) | 105 | 105 | 91 | 85 | 83 | 78 |
Shares Change | 11.57% | 15.58% | 6.67% | 2.97% | 6.22% | 6.31% |
EPS (Basic) | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
EPS (Diluted) | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -1.07 | -1.09 | -1.1 | -0.99 | -0.92 | -1.26 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -6334.15% | -2877.96% | -1327.45% | -1046.96% | -1198.95% | -2922.50% |
Profit Margin | -5127.11% | -2470.76% | -1249.73% | -874.52% | -1200.21% | -3309.36% |
Free Cash Flow Margin | -3833.67% | -1828.20% | -711.12% | -604.65% | -599.20% | -2875.13% |
EBITDA | -1.74 | -1.7 | -2.03 | -1.7 | -1.83 | -1.28 |
D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
EBIT | -1.76 | -1.72 | -2.05 | -1.71 | -1.84 | -1.28 |